44 results on '"Lymphoma, T-Cell, Cutaneous"'
Search Results
2. Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
3. Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma
4. Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
5. Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
6. Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
7. Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
8. Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)
9. Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma
10. Topical Romidepsin to Treat Early-Stage Cutaneous T-Cell Lymphoma
11. Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors
12. O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell Lymphoma
13. Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma
14. Anti-Tac(Fv)-PE38 (LMB-2) to Treat Cutaneous T-Cell Lymphomas
15. Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers
16. Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma
17. Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
18. Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma
19. Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery
20. Analysis of Genes Present in Cutaneous T-cell Lymphoma Cells
21. Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease
22. RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors
23. Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia
24. Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy
25. Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction
26. Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
27. Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
28. FAU in Treating Patients With Advanced Solid Tumors or Lymphoma
29. 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
30. 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer
31. PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma
32. PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
33. 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
34. Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction
35. 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas
36. Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma
37. Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma
38. MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas
39. Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma
40. 506U78 in Treating Patients With Recurrent or Refractory Cutaneous T-cell Lymphoma
41. Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides
42. 506U78 in Treating Patients With Lymphoma
43. O6-benzylguanine and Carmustine in Treating Patients With Stage IA-IIA Cutaneous T-cell Lymphoma
44. Treatment of Tac-Expressing Cutaneous T-Cell Lymphoma (CTCL) and Adult T-Cell Leukemia (ATL) With Yttrium-90 Radiolabeled Anti-Tac
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.